Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2021)
16 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 16, 2021
Slide 1: AGM November 2021
AGM NOVEMBER 2021 ---------------- ASX: ANR
Slide 2: Developing the next generation of gastrointestinal health products
Developing the next generation of gastrointestinal health products • More than ever, the world is looking for safe and effective solutions for gastrointestinal tract (GIT or ‘gut’) symptoms and disorders • 40% of global consumers say digestive complaints have had some influence on their lives 1 • Ir
Slide 3: Achievements
Achievements Human health assets Animal health assets Achievements Achievements • All components GRAS (FDA: generally regarded as • Detach® patents granted in Australia and Japan safe) • Developed new bromelain-based formulations to • Patent pending formulation with functional offer convenient deliv
Slide 4: Program pipeline
Program pipeline PRECLINICAL CLINICAL COMMERCIAL PROGRAM DELIVERY DISCOVERY REGISTRATION In-Vivo Proof of RIGHTS In-Vitro Pivotal (animal) Concept Irritable Bowel Syndrome (Diarrhoea) Oral GaRP 18-65 ✓ ✓ ✓ Mar '22 Sep '22 Global Minitabs HUMAN Moderate Depression, Anxiety or Stress Oral 3FDC 15-55 ✓
Slide 5: Building a Health Portfolio
Building a Health Portfolio • Anatara aims to be the ‘go to’ company for gut health solutions, including treatments, diagnostics and advice • Focused on delivering evidence-based treatments and solutions for GIT health needs GaRP Technology to provide a pipeline of products • Potential to apply our
Slide 6: Global consumer health market opportunity in managing gastrointestinal tract symptoms
Global consumer health market opportunity in managing gastrointestinal tract (GIT or ‘gut’) symptoms and general wellbeing is enormous >US$8 billion spend on OTC and digestive remedies alone 2,3 >US $1 billion market in IBS alone 4 Probiotic supplements Other GI supplements OTC digestive supplements
Slide 7: GaRP technology
GaRP technology A potential break though for gut health Unique knowledge of Ingredients are Well-characterised Synergistic effects Gut-Brain bromelain’s ‘fingerprint’ GRAS proprietary mix Connection Formulation Function within formulation and potential impact on symptoms Component Restores Influence
Slide 8: GaRP
GaRP One product, multiple benefits Scientifically designed to manage and control background IBS symptoms as well as episodic flare ups Designed as an everyday option to manage the causes and relieve symptoms of IBS such as pain, cramping, gas, bloating, diarrhoea and/or constipation Coated componen
Slide 9: Clinical trial – Irritable Bowel Syndrome (diarrhoea subtype; IBS-D)
Clinical trial – Irritable Bowel Syndrome (diarrhoea subtype; IBS-D) Title: Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS-D patients: A Randomized, Double-blind, Placebo controlled virtual clinical trial Population: Males and female
Slide 10: 3FDC Positively Influencing the Gut-Brain Connection
3FDC Positively Influencing the Gut-Brain Connection Aims to assist homeostasis of the “gut” to promote overall health and wellbeing Targeting modulation of psychobiological processes driving anxiety-related disorders Coated components released in the large intestine (colon) to positively influence
Slide 11: Clinical trial – Psychological functioning
Clinical trial – Psychological functioning Title: The effects of 3FDC dietary supplementation on psychological functioning in an adult population Population: ~100 males or females 18-55 years of age with with moderate levels of depression, anxiety, or stress symptoms indicated by the Depression, Anx
Slide 12: Commercialisation Strategy for GaRP Pipeline including 3FDC
Commercialisation Strategy for GaRP Pipeline including 3FDC GaRP is a potential breakthrough, evidence based product • targeting the cause of IBS, not just a product that Huge underlying demand given IBS prevalence across key markets treats symptoms 2 3 Key markets • North America, Europe, select As
Slide 13: Licensing discussion progress and portfolio diversification
Licensing discussion progress and portfolio diversification Anatara is progressing licensing discussions with international consumer health companies for GaRP and evaluating approach • ‘Local Hero’ licensing approach – forming partnerships with regional leaders in 'gut' health taking advantage of lo
Slide 14: Glossary
Glossary IBS Irritable bowel syndrome (IBS) is a condition that affects the colon (large bowel). Key symptoms include abdominal pain or discomfort, stomach bloating, chronic diarrhoea or constipation, or alternating between the two. IBD Inflammatory bowel diseases are conditions in which the lining
Slide 15: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company).
Slide 16: Contact Anatara Lifesciences Ltd
Contact Anatara Lifesciences Ltd Steven Lydeamore, Chief Executive Officer +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — Shareholder Meeting (November 2021) on 6ix